Barclays PLC Increases Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Barclays PLC increased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 77.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 128,344 shares of the company's stock after purchasing an additional 56,190 shares during the quarter. Barclays PLC owned approximately 0.18% of Nurix Therapeutics worth $2,884,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. Driehaus Capital Management LLC acquired a new position in Nurix Therapeutics during the second quarter worth approximately $26,778,000. Samlyn Capital LLC bought a new position in shares of Nurix Therapeutics during the 2nd quarter worth approximately $12,177,000. Sumitomo Mitsui Trust Group Inc. acquired a new position in shares of Nurix Therapeutics during the 3rd quarter worth approximately $12,432,000. FMR LLC raised its stake in Nurix Therapeutics by 675.9% in the 3rd quarter. FMR LLC now owns 586,902 shares of the company's stock valued at $13,188,000 after acquiring an additional 511,256 shares during the period. Finally, Patient Square Capital LP acquired a new stake in Nurix Therapeutics during the 3rd quarter valued at $7,320,000.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,546 shares of the firm's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $24.28, for a total value of $86,096.88. Following the sale, the chief financial officer now owns 33,724 shares of the company's stock, valued at $818,818.72. This trade represents a 9.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Christine Ring sold 5,760 shares of Nurix Therapeutics stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total value of $128,044.80. Following the sale, the insider now owns 24,592 shares of the company's stock, valued at approximately $546,680.16. This trade represents a 18.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,401 shares of company stock valued at $437,453 in the last three months. Company insiders own 9.80% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. HC Wainwright upped their price objective on shares of Nurix Therapeutics from $30.00 to $35.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. Oppenheimer increased their price target on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the company an "outperform" rating in a report on Wednesday, September 4th. Robert W. Baird initiated coverage on Nurix Therapeutics in a report on Friday, September 6th. They set an "outperform" rating and a $26.00 price objective for the company. BMO Capital Markets started coverage on Nurix Therapeutics in a research note on Friday, December 6th. They set an "outperform" rating and a $35.00 target price on the stock. Finally, Jefferies Financial Group began coverage on Nurix Therapeutics in a research note on Friday, October 11th. They issued a "buy" rating and a $41.00 price target for the company. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $30.35.

Nurix Therapeutics Trading Down 2.1 %

Shares of NRIX stock traded down $0.41 during trading hours on Wednesday, hitting $19.57. 351,436 shares of the company were exchanged, compared to its average volume of 907,689. Nurix Therapeutics, Inc. has a 52-week low of $7.65 and a 52-week high of $29.56. The firm has a fifty day simple moving average of $23.25 and a 200 day simple moving average of $22.42. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -6.73 and a beta of 2.12.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The firm had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. Sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 EPS for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.